PROBIOTICS - A PROBABLE THERAPEUTIC AGENT FOR SPONDYLOARTHROPATHY

Area of Science:

• Immunology
• Microbiology
• Rheumatology

Background:

• Spondyloarthropathy (SpA) encompasses joint diseases of the vertebral column, with ankylosing spondylitis being a key focus due to its unique progression.
• Human leukocyte antigen (HLA)-B27 is implicated in SpA progression, exhibiting molecular similarities and immunological cross-reactivity with gut microbes.
• Current SpA treatments carry risks of side effects and complications.

Purpose of the Study:

• To explore the intricate relationship between SpA pathogenesis and the gut microbiome.
• To evaluate the potential of probiotics as an alternative therapy for managing SpA and its progression.

Main Methods:

• Review of existing research on SpA, HLA-B27, gut microbiome interactions, and probiotic efficacy.
• Analysis of how probiotics influence gut microflora to mitigate SpA predisposition.

Main Results:

• Probiotics have demonstrated effectiveness in managing various SpA entities, including ankylosing spondylitis.
• Probiotics alter gut microflora composition, potentially reducing SpA susceptibility.
• Probiotic therapy offers a promising alternative with a favorable side effect profile compared to conventional medications.

Conclusions:

• The gut microbiome plays a significant role in SpA pathogenesis.
• Probiotics represent a viable therapeutic strategy to treat or slow SpA progression.
• Targeting the gut-SpA axis with probiotics could lead to improved patient outcomes.